Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib: Two case reports

Strahlentherapie und Onkologie

Volumn 190, Issue 2, 2014, Pages 229-232

  Schulze, B ^a   Meissner, M ^a   Wolter, M ^a   Rodel C ^a   Weiss, C ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Melanoma; Metastases; Radiodermatitis; Survival; Toxicity

Indexed keywords

ALPHA INTERFERON; SKIN CREAM; UREA; VEMURAFENIB;

ADJUVANT THERAPY; ADULT; AMELANOTIC MELANOMA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DELAYED HYPERSENSITIVITY; DESQUAMATION; DRUG WITHDRAWAL; EDEMA; EROSION; ERYTHEMA; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HUMAN; HYPERPIGMENTATION; INGUINAL LYMPH NODE; LYMPH NODE DISSECTION; MELANOMA; PRIMARY TUMOR; RADIATION DERMATITIS; RADIATION DOSE; RADIATION FIELD; SKIN MANIFESTATION; SKIN METASTASIS; SYSTEMIC THERAPY; TOPICAL TREATMENT; WIDE EXCISION;

BRAIN NEOPLASMS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; CRANIAL IRRADIATION; FACIAL DERMATOSES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; INTERDISCIPLINARY COMMUNICATION; MALE; MELANOMA; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; RADIODERMATITIS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SCALP DERMATOSES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84893727436     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0474-3     Document Type: Article

References (23)

1. Amer MH, Al-Sarraf M, Baker LH et al (1978) Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42:660-668
2. Anker CJ, Ribas A, Grossmann AH et al (2013) Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol
3. Ascierto PA, Kirkwood JM, Grob JJ et al (2012) The role of BRAF V600 mutation in melanoma. J Transl Med 10:85
4. Boussemart L, Boivin C, Claveau J et al (n d) Vemurafenib and Radiosensitization. JAMA Dermatol 2013:1-3
5. Boussemart L, Routier E, Mateus C et al (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 24:1691-1697
6. Brose MS, Volpe P, Feldman M et al (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000
7. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
8. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
9. Dummer R, Rinderknecht J, Goldinger SM (2012) Ultraviolet a and photosensitivity during vemurafenib therapy. N Engl J Med 366:480-481
10. Dziggel L, Segedin B, Podvrsnik NH et al (2013) Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol 189:364-366
11. Fife KM, Colman MH, Stevens GN et al (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293-1300
12. Fokas E, Steinbach JP, Rodel C (2013) Biology of brain metastases and novel targeted therapies: time to translate the research. Biochim Biophys Acta 1835:61-75
13. Gani C, Muller AC, Eckert F et al (2012) Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors. Strahlenther Onkol 188:148-153
14. Narayana A, Mathew M, Tam M et al (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol
15. Oberholzer PA, Kee D, Dziunycz P et al (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316-321
16. Ramakrishna N, Margolin KA (2013) Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am Soc Clin Oncol Educ Book 2013:399-403
17. Retsas S, Gershuny AR (1988) Central nervous system involvement in malignant melanoma. Cancer 61:1926-1934
18. Sampson JH, Carter JH Jr, Friedman AH et al (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11-20
19. Satzger I, Degen A, Asper H et al (2013) Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy. J Clin Oncol 31:e220-e222
20. Sinha R, Edmonds K, Newton-Bishop JA et al (2012) Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 167:987-994
21. Sloan AE, Nock CJ, Einstein DB (2009) Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 16:248-255
22. Staudt M, Lasithiotakis K, Leiter U et al (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213-1218
23. Su F, Viros A, Milagre C et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215